Description
Indication & Scope
JinSuXi (Silevimig) contains silevimig, a recombinant fully human bispecific monoclonal antibody for passive immunization against rabies virus following rabies virus exposure in adults.
- Mechanism: Binds to two distinct epitopes on the rabies virus glycoprotein, neutralizing the virus and preventing viral entry into host cells.
- Drug class: Recombinant fully human anti-rabies virus bispecific monoclonal antibody.
- Clinical use: Passive immunization following rabies virus exposure, administered in combination with rabies vaccine.
| Generic Name | Silevimig |
| Brand Name | JinSuXi® |
| Ingredient | Each vial contains 2 mg silevimig in 1 mL. |
| Dosage Form | Solution for Injection. |
| Package | One vial (1 mL). |
| Conditions Treated | Passive immunization in adults following rabies virus exposure, administered in combination with rabies vaccine. |
| Taboos | Hypersensitivity to silevimig or any component of the product. |
| Place of origin | China |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Refer to the approved package labeling. |
| Manufacturer | Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20260045 |
| Date of Revision | 2026 |
| Shelf Life | Refer to the approved package labeling |
How to use ?
Recommended Dose: Administer according to the approved dosage regimen for rabies post-exposure prophylaxis in combination with rabies vaccine.
Time: Administer as soon as possible after rabies virus exposure.
Instructions for use: Administer by injection according to the approved prescribing information and rabies post-exposure prophylaxis guidelines.
Interaction: Intended for use in combination with rabies vaccine as part of rabies post-exposure prophylaxis.
Side effects: Injection-site reactions, headache, fever, fatigue, and other adverse reactions reported with antibody-based rabies passive immunization products.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is JinSuXi® used for?
It is used for passive immunization following rabies virus exposure in adults, in combination with rabies vaccine.
How does JinSuXi® work?
It binds to two distinct epitopes on the rabies virus glycoprotein, neutralizing the virus and preventing viral entry into host cells.
What is JinSuXi® (Silevimig)?
Jinsuxi(silevimig) is a recombinant fully human bispecific antibody for passive immunization against rabies virus.
What are the common side effects?
Common adverse reactions include injection-site reactions, headache, fever, and fatigue.
JinSuXi® Silevimig | Rabies Passive Immunization | DengYueRX
INN: Silevimig
Indications: Passive immunization in adults following rabies virus exposure, in combination with rabies vaccine.
Dosage Form: Solution for Injection
Strength: 2mg(1mL)
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
